![[fetch_key]](https://stocktradeupdates.com/wp-content/uploads/new_logos/SUNPHARMA.png)
Share the post "SUN PHARMACEUTICAL INDUSTRIES’s Q3 2024-25 Latest News: Profit Grows by 13.76% YoY"
Highlights
🔹 The presented financial data is Consolidated to provide a comprehensive overview of the company performance. 🔹 Sales over the Year and quarter: The company experienced a substantial growth of 10.46 % in the past year, substantial increase in net sales/revenue by 2.89 %. 🔹 Income over the Year and quarter: There has been decline in other income over the past year which is -17.15 %, Marginal decrease of -57.78% in other income during this quarter. 🔹 Profit over the Year and quarter: Significant improvement in profitability for SUN PHARMACEUTICAL INDUSTRIES. Notable increase of 13.76 % in net profit Year to Year, SUN PHARMACEUTICAL INDUSTRIES’s profitability dropped by -4.09 % Quarter to Quarter. 🔹 EPS over the Year and quarter: EPS increased by 15.24 % Year to Year. EPS decreased by -4.72 % in previous quarter. Analysis needed for shareholder value.
| Metrics | Previous Year | Previous Quarter | Current Quarter | Quarter to Quarter Difference | Year to Year Difference |
|---|---|---|---|---|---|
| Sales | Rs. 12380.7 Cr | Rs. 13291.39 Cr | Rs. 13675.46 Cr | + 2.89 % | + 10.46 % |
| Expenses | Rs. 8911.36 Cr | Rs. 9352.43 Cr | Rs. 9671 Cr | + 3.41 % | + 8.52 % |
| Operating Profit | Rs. 3469.34 Cr | Rs. 3938.96 Cr | Rs. 4004.46 Cr | + 1.66 % | + 15.42 % |
| OPM % | 28.02 % | 29.64 % | 29.28 % | -0.36 % | + 1.26 % |
| Other Income | Rs. 180.39 Cr | Rs. 354 Cr | Rs. 149.45 Cr | -57.78 % | -17.15 % |
| Interest | Rs. 34.73 Cr | Rs. 69.17 Cr | Rs. 51.51 Cr | -25.53 % | + 48.32 % |
| Depreciation | Rs. 622.14 Cr | Rs. 625.91 Cr | Rs. 630.56 Cr | + 0.74 % | + 1.35 % |
| Profit before tax | Rs. 2992.86 Cr | Rs. 3597.88 Cr | Rs. 3471.84 Cr | -3.5 % | + 16 % |
| Tax % | 14.41 % | 15.77 % | 16.08 % | + 0.31 % | + 1.67 % |
| Net Profit | Rs. 2560.54 Cr | Rs. 3037.33 Cr | Rs. 2912.98 Cr | -4.09 % | + 13.76 % |
| EPS in Rs | Rs. 10.5 | Rs. 12.7 | Rs. 12.1 | -4.72 % | + 15.24 % |
Today, we’re looking at SUN PHARMACEUTICAL INDUSTRIES’s financial performance for the Q3(Dec 2024-25).Starting with the top line, the company reported a robust year-over-year sales growth of 10.46 %. However, it did see a marginal increase of 2.89 % from the previous quarter. Expenses ticked up slightly by 3.41 % quarter-on-quarter, aligning with the annual rise of 8.52 %. Operating profit, while up 15.42 % compared to last year, faced a quarter-on-quarter increase of 1.66 %, signaling a short-term expansion in margins.
The Operating Profit Margin (OPM) % echoes this narrative, showing resilience on an annual basis with an increase of 1.26 %, but a shrinkage of -0.36 % sequentially. Other income fell by -57.78 % compared to the last quarter, despite an annual decline of -17.15 %. Interest expenses dropped significantly by -25.53 % from the previous quarter, yet the year-over-year increase remains at a moderate 48.32 %. Depreciation costs climbed by 0.74 % quarter-on-quarter, whereas on an annual scale, they saw an increase of 1.35 %. Profit before tax grew annually by 16 % but saw a reduction from the preceding quarter by -3.5 %.
Tax expenses as a percentage of profits increased slightly by 1.67 % compared to last year, with a more notable quarter-on-quarter increase of 0.31 %. Net profit rose by 13.76 % year-on-year but witnessed a -4.09 % contraction from the last quarter. And finally, Earnings Per Share (EPS) displayed an annual uptick of 15.24 % but a quarterly fall of -4.72 %. In summary, SUN PHARMACEUTICAL INDUSTRIES’s annual performance indicates steady growth, although the quarter-on-quarter figures suggest some areas may require strategic attention.
| Metrics | Previous Year | Previous Quarter | Current Quarter | Quarter to Quarter Difference | Year to Year Difference |
|---|---|---|---|---|---|
| Sales | Rs. 12380.7 Cr | Rs. 13291.39 Cr | Rs. 13675.46 Cr | + 2.89 % | + 10.46 % |
| Expenses | Rs. 8911.36 Cr | Rs. 9352.43 Cr | Rs. 9671 Cr | + 3.41 % | + 8.52 % |
| Operating Profit | Rs. 3469.34 Cr | Rs. 3938.96 Cr | Rs. 4004.46 Cr | + 1.66 % | + 15.42 % |
| Net Profit | Rs. 2560.54 Cr | Rs. 3037.33 Cr | Rs. 2912.98 Cr | -4.09 % | + 13.76 % |
| EPS in Rs | Rs. 10.5 | Rs. 12.7 | Rs. 12.1 | -4.72 % | + 15.24 % |
In reviewing SUN PHARMACEUTICAL INDUSTRIES’s 2024-25(Q3) financial snapshot, key trends emerge, shedding light on the company’s performance.Sales saw a robust 10.46 % year-on-year growth, however, there was a minor increase of 2.89 % from the previous quarter. Expenses rose by 8.52 % compared to the previous year, with a 3.41 % increase quarter-on-quarter. Operating Profit surged by 15.42 % annually, and saw a 1.66 % increase from the last quarter.
Net Profit showed yearly increase of 13.76 %, and experienced a -4.09 % decrease from the previous quarter. Earnings Per Share (EPS) rose by 15.24 % annually, however dipped by -4.72 % compared to the last quarter. In essence, while SUN PHARMACEUTICAL INDUSTRIES exhibits strong annual growth indicators, short-term fluctuations suggest the need for agile strategies to navigate market dynamics effectively. That’s all for now in the financial sector.
![[fetch_key]](https://stocktradeupdates.com/wp-content/uploads/new_logos/GILLETTE.png)
